Variable of interest | Value | TIO vs UC | TIO vs GLY |
---|---|---|---|
Base case | 224,850 | 10,456 | |
Discount rate | 0 % | 187,684 | 13,206 |
5 % | 249,658 | 8523 | |
Time horizon | 5 years | 592,149 | Dominating |
10 years | 326,192 | 2233 | |
20 years | 235,715 | 9641 | |
Treatment duration | 1 year | 102,727 | 9849 |
10 years | 294,652 | 12,081 | |
Life (35 years) | 330,299 | 14,962 | |
Sex | Males only | 230,862 | 9646 |
Females only | 220,021 | 11,141 | |
Start age | 40 | 320,470 | 2119 |
80 | 240,894 | 11,043 | |
GOLD start dist | All start in GOLD II | 225,925 | 12,878 |
All start in GOLD III | 224,903 | 9172 | |
All start in GOLD IV | 217,926 | 7084 | |
Mortality | Normal mortality (not adjusted for COPD) for all GOLD states | 232,402 | 11,522 |
20 % higher excess mortality (Sev Ex) | 204,979 | 12,424 | |
20 % lower excess mortality (Sev Ex) | 247,036 | 8093 | |
Effect of tiotropium on Sev Ex | Low 95 % CI from studiesa (RR Sev Ex) | 103,232 | 114,589 |
High 95 % CI from studiesa (RR Sev Ex) | 5,845,054 | 2859 | |
Direct costs of Sev Ex | 20 % higher | 221,336 | 5665 |
20 % lower | 228,367 | 15,246 | |
QoL loss of Sev Ex exacerbations | 0 % loss | 225,934 | 10,528 |
20 % loss | 221,429 | 10,235 |